Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous Epstein-Barr virus-specific cytotoxic T lymphocytes (Northwestern University)
- Development stage
- Unknown
- Lead developer
- Northwestern University
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs) are an adoptive cellular immunotherapy developed by **Northwestern University**. This therapy involves the ex vivo expansion of a patient's own T cells that have been specifically sensitized to recognize and eliminate cells infected with the **Epstein-Barr virus (EBV)**. It is primarily investigated for the treatment and prevention of EBV-induced **post-transplant lymphoproliferative disorder (PTLD)** in recipients of solid organ or hematopoietic stem cell transplants. By restoring EBV-specific immunity, these CTLs target EBV-positive B-cell proliferations, providing a targeted alternative to traditional chemotherapy or reduction of immunosuppression.
- Other names
- autologous EBV-CTLsautologous EBV-specific T cellsautologous EBV-specific cytotoxic T lymphocytes
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on autologous Epstein-Barr virus-specific cytotoxic T lymphocytes (Northwestern University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous Epstein-Barr virus-specific cytotoxic T lymphocytes (Northwestern University).